STOCK TITAN

CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
partnership

CytomX Therapeutics (Nasdaq: CTMX) achieved a preclinical milestone in its collaboration with Regeneron, triggering a $5 million payment to CytomX. The milestone concerns one of the collaboration’s lead programs and is the first achieved under the partnership, which began in 2022 and expanded in June 2026.

The collaboration combines CytomX’s PROBODY masking technology with Regeneron’s bispecific antibody platform to develop antibodies designed to activate in the tumor environment rather than throughout the body. Regeneron funds all preclinical and clinical development and commercialization activities. Under the expanded collaboration, CytomX is eligible for up to approximately $4 billion in total potential target nomination and milestone payments, plus tiered royalties on global net sales of any potential covered products.

Loading...
Loading translation...
4 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.Up to approximately $4 billion in total potential target nomination and milestone payments available under the expanded collaboration. 9.2× market cap
  • Moderate point$5 million milestone payment triggered by achieving a preclinical milestone in a lead Regeneron collaboration program. 1.2% of market cap
  • Moderate pointRegeneron funds all preclinical and clinical development and commercialization activities under the collaboration.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Tiered royalties available to CytomX on global net sales of any potential products covered by the collaboration.

Negative

  • None.

Key Figures

Preclinical milestone payment: $5 million Potential collaboration milestones: Up to approximately $4 billion
Preclinical milestone payment
$5 million
Triggered by achievement of a milestone in the Regeneron collaboration
Potential collaboration milestones
Up to approximately $4 billion
Expanded collaboration; total potential target nomination, preclinical, clinical, regulatory and commercial milestones

Previous Partnership Reports

1 past event · Latest: Jun 03
Same Type 1 event
  1. Jun 03

    Collaboration expansion

    24h Move
    +1.9%

    Expanded Regeneron collaboration set target-nomination payment and potential milestone terms for bispecific programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

bispecific antibodies, proteases
2 terms
bispecific antibodies medical
"identify and validate conditionally active bispecific antibodies"
Engineered proteins that can attach to two different biological targets at once, like a two-headed key that fits two locks simultaneously; in medicine they often link immune cells to diseased cells or block two disease pathways at the same time. Investors care because this dual-action design can improve effectiveness or open new treatment options, but it also raises development complexity, manufacturing cost and regulatory risk, affecting a biotech company’s value and partnerships.
proteases medical
"activated by proteases highly enriched in the tumor microenvironment"
Proteases are enzymes that cut proteins into smaller pieces, like scissors trimming fabric to change its shape and function. They matter to investors because drugs or diagnostics that target or mimic proteases can alter disease processes, create new treatments, or become biomarkers, which affects a company’s drug pipeline, regulatory pathway, and potential revenue. Success or failure in protease-related programs often drives clinical value and stock movement in biopharma firms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

- CytomX to receive $5 million preclinical milestone payment -

- The CytomX and Regeneron collaboration began in 2022 and was expanded in June 2026 -

EMERYVILLE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the achievement of a preclinical milestone for one of the lead programs in its collaboration with Regeneron, triggering a $5 million milestone payment.

The Regeneron and CytomX collaboration agreement combines CytomX’s PROBODY® therapeutic masking technology with Regeneron’s Veloci-Bi® bispecific antibody platform to develop bispecifics that remain inactive within systemic circulation until activated by proteases highly enriched in the tumor microenvironment. This approach has the potential to broaden the therapeutic window and minimize off-target side effects for next-generation T-cell engaging therapies.

“Achievement of this first milestone from our Regeneron partnership represents the translation of promising science towards the clinic and underscores the potential synergistic approach of combining our respective technologies. Following the expansion of our collaboration in June 2026, we are excited to advance our aligned vision of bringing highly innovative new treatment options to cancer patients,” said Sean McCarthy, D. Phil, CEO and Chairman of CytomX.

About the Regeneron Collaboration
Under the terms of the Regeneron and CytomX agreement, the companies collaborate on discovery activities to identify and validate conditionally active bispecific antibodies. Regeneron is responsible for funding all preclinical and clinical development and commercialization activities. CytomX is eligible to receive total potential target nomination payments, preclinical, clinical, regulatory and commercial milestones covered under the scope of the expanded collaboration up to approximately $4 billion. CytomX is also eligible to receive tiered royalties on global net sales for any potential products covered under the collaboration.

About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated antibody drug conjugate armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Regeneron. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond CytomX’s control, and may cause the actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements, including those related to the future potential of partnerships or collaboration agreements and projected cash runway. These forward-looking statements include, but are not limited to, statements relating to the potential benefits, safety and efficacy or progress of CytomX’s or any of its collaborative partners’ product candidates, the potential benefits or applications of CytomX’s PROBODY® therapeutic platform, CytomX’s or its collaborative partners’ ability to develop and advance product candidates into and successfully complete clinical trials and to achieve other preclinical, clinical, regulatory and commercial milestones. Accordingly, you should not place undue reliance on these forward-looking statements. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the unproven nature of CytomX’s novel PROBODY® therapeutic technology; uncertainties around CytomX’s ability to raise sufficient funds to carry out its planned research and development; the early stage of CytomX’s or its collaborators’ clinical trial product candidates, which are in the initial stages of clinical development, and its or their other product candidates, which are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties, including the possibility that the results of preclinical research and early clinical trials may not be predictive of future results; the risk that interim or preliminary clinical data may change as more patient data become available; the possibility that CytomX’s or its collaborators’ clinical trials will not be successful; the possibility that current preclinical research may not result in additional product candidates; the possibility that CytomX or its collaborators may not be able to realize the full potential of its or their product candidates; possible regulatory developments in the United States and foreign countries, including China and the European Union; and the risk that CytomX or its collaborators may incur higher costs than expected for research and development. Additional applicable risks and uncertainties include those relating to CytomX’s or its collaborator’s preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2026 and in CytomX’s subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. Except as required by applicable law, CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.

PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc. All other trademarks are the properties of their respective owners.

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
LifeSci Advisors
Corey Davis
cdavis@lifescienceadvisors.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What milestone payment will CytomX receive from its Regeneron collaboration?

CytomX will receive $5 million after achieving a preclinical milestone for one of the collaboration’s lead programs. This is the first milestone achieved under the partnership, which began in 2022 and expanded in June 2026.

What payments is CytomX eligible for under the expanded Regeneron collaboration?

CytomX is eligible for up to approximately $4 billion in total potential target nomination payments and preclinical, clinical, regulatory and commercial milestones. It is also eligible for tiered royalties on global net sales of any potential products covered by the collaboration.

Keep reading